Essential tremor: Epidemiology, diagnosis, and treatment

Neurologist

Volumn 10, Issue 5, 2004, Pages 250-258

  Sullivan, Kelly L ^a   Hauser, Robert A ^a,b   Zesiewicz, Theresa A ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

Deep brain stimulation; Essential tremor; Primidone; Propranolol; Thalamotomy

Indexed keywords

ACETAZOLAMIDE; ALPRAZOLAM; ANTICONVULSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BOTULINUM TOXIN A; CLONIDINE; CLOZAPINE; GABAPENTIN; METHAZOLAMIDE; NIMODIPINE; PRIMIDONE; PROGABIDE; PROPRANOLOL; SOTALOL; TOPIRAMATE; TRAZODONE;

ACUTE TOXICITY; AGRANULOCYTOSIS; ANOREXIA; ATAXIA; AUTOSOMAL DOMINANT INHERITANCE; BRADYCARDIA; BRAIN DEPTH STIMULATION; BRONCHOSPASM; CLINICAL FEATURE; CLINICAL TRIAL; COGNITIVE DEFECT; CONFUSION; COUGHING; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DIZZINESS; DRUG CONTRAINDICATION; EPIDEMIOLOGICAL DATA; ESSENTIAL TREMOR; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FLU LIKE SYNDROME; GENE LOCUS; GENETIC SUSCEPTIBILITY; GENETICS; HAND GRIP; HUMAN; HYPOTENSION; INJECTION PAIN; LARYNX DISORDER; MALAISE; MUSCLE WEAKNESS; NAUSEA; NEUROLOGIC EXAMINATION; NEUROSURGERY; PARESTHESIA; PATHOGENESIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEDATION; SEX RATIO; SIDE EFFECT; SOMNOLENCE; THALAMOTOMY; TREATMENT INDICATION; VERTIGO; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

ADRENERGIC BETA-AGONISTS; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BOTULINUM TOXINS; ESSENTIAL TREMOR; HUMANS; THALAMUS;

EID: 4544357835     PISSN: 10747931     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.nrl.0000138736.07840.b2     Document Type: Review

References (112)

1. Deuschl G, Koller WC. Essential tremor. Neurology. 2000;54(suppl 4):S1.
2. Koller WC, Biary N, Cone S. Disability in essential tremor: effect of treatment. Neurology. 1986;36:1001-1004.
3. Rautakorpi I. Essential tremor: an epidemiological, clinical, and genetic study. Academic dissertation. Turku, Finland.
4. Rajput AH, Offord KP, Beard CM, et al. Essential tremor in Rochester, Minnesota: a 45-year study. J Neurol Neurosurg Psychiatry. 1984;47:466-470.
5. Louis ED, Dure LS, Pullman S. Essential tremor in childhood: a series of nineteen cases. Mov Disord. 2001;16:921-923.
6. Hornabrook RW, Nagurney JT. Essential tremor in Papau New Guinea. Brain. 1976;99:659-672.
7. Louis ED, Ford B, Frucht S. Factors associated with increased risk of head tremor in essential tremor: a community-based study in northern Manhattan. Mov Disord. 2003;18:432-436.
8. Louis ED, Barnes L, Ford B, et al. Ethnic differences in essential tremor. Arch Neurol. 2000;57:723-727.
9. Louis ED, Ottman R. How familial is familial tremor? Genetic epidemiology of essential tremor. Neurology. 1996;46:1200-1205.
10. Bain PG, Findley LJ, Atchison P, et al. Assessing tremor severity. J Neurol Neurosurg Psychiatry. 1993;56:868-873.
11. Louis ED. Etiology of essential tremor: should we be searching for environmental causes? Mov Disord. 2001;16:822-829.
12. Louis ED, Ford B, Frucht S, et al. Risk of tremor and impairment from tremor in relatives or patients with essential tremor: a community-based family study. Ann Neurol. 2001;49:761-769.
13. Higgins JJ, Loveless JM, Jankovic J, et al. Evidence that a gene for essential tremor maps to chromosome 2p in four families. Mov Disord. 1998;13:972-977. Erratum. Mov Disord. 1999;14:200.
14. Higgins JJ, Loveless JM, Jankovic J, et al. Evidence that a gene for essential tremor maps to chromosome 2p in four families. Mov Disord. 1998;13:972-977. Erratum. Mov Disord. 1999;14:200.
15. Louis ED, Greene P. Essential tremor: In: Rowland LP, ed. Merritt's Textbook of Neurology. 10th ed. Philadelphia: Lea & Fibiger.
16. Elble RJ. Animal models of action tremor [review]. Mov Disord. 1998;13(suppl 3):35-39.
17. Boecher H, Wills AJ, Ceballos-Baumann A, et al. The effect of ethanol on alcohol-responsive essential tremor: a positron emission tomography study. Ann Neurol. 1996;39:650-658.
18. Schuurman PR, Bosch DA, Bossuty RMM, et al. A comparison of continuous thalamic stimulator and thalamotomy for suppression of severe tremor. N Engl J Med. 2000;342:461-468.
19. Mylle G, van Bogaert L. Du tremblement essential non familial. Mschr Psychiatr Neurol. 1948;115:80-90.
20. Hassler R. Zur Pathologischen Anatomie des senilen und des parkinsonistischen Tremor. J Psychol Neurol. 1939;49:193-230.
21. Mylle G, van Bogaert L. Etudes anatomo-cliniques de syndromes hypercinetiques complexes. I. Sur le tremblement familial. Mschr Psychiatr Neurol. 1940;103:28-43.
22. Cross AJ, Misra A, Sandilands A, et al. Effect of chlormethiazole, dizocilpine and pentobarbital on harmaline-induced increase of cerebellar cyclic GMP and tremor. Psychopharmacology. 1993;111:96-98.
23. Sinton CM, Krosser BI, Walton KD, et al. The effectiveness of different isomares of octanol as blockers of harmaline-induced tremor. Pflüger's Arch. 1989;414:31-36.
24. Mally J, Baranyi M, Vizi ES. Change in the concentrations of amino acids in CSF and serum in patients with essential tremor. J Neural Transm. 1996;103:555-560.
25. Hubble JP, Busenbark KL, Pahwa R, et al. Clinical expression of essential tremor: effects of gender and age. Mov Disord. 1997;12:969-972.
26. Louis ED, Ford B, Wendt KJ, Cameron G. Clinical characteristics of essential tremor: data from a population-based cohort. Mov Disord. 1998;13:803-808.
27. Louis ED, Marcer K, Cote K, et al. Differences in the prevalence of essential tremor among elderly African-Americans, Caucasians and Hispanics in northern Manhattan. Arch Neurol. 1995;52:1201-1205.
28. Koller WWC, Hristova A, Brin M. Pharmacological treatment of essential tremor. Neurology. 2000;54(suppl 4):S30-S38.
29. Hsu YD, Chang MK, Sung SC, et al. Essential tremor: clinical, lectromyographical and pharmacological studies in 146 Chinese patients. Zhonghua Yi Xue Za Zhi (Taipei). 1990;45:93-99.
30. Louis ED, Wendt KJ, Pullman SL. Is essential tremor symmetric? Observation data from a community-based study of essential tremor. Arch Neurol. 1998;55:1553-1559.
31. Biary N, Koller W. Handedness and essential tremor. Arch Neurol. 1985;42:1082-1083.
32. Singer C, Sanchez-Ramos J, Weiner WJ. Gait abnormality in essential tremor. Mov Disord. 1994;9:193-200.
33. Lou JS, Jankovic J. Essential tremor: clinical correlates in 350 patients. Neurology. 1991;41:234-238.
34. Koller W, Busenbark K, Miner K, et al. The relationship of essential tremor to other movement disorders: report on 678 patients. Ann Neurol. 1994;35:717-723.
35. Rajput AH, Jamieson H, Hirsh S, et al. Relative efficacy of alcohol and propranolol in action tremor. Can J Neurol Sci. 1975;2:31-35.
36. Koller WC, Biary N. Effect of alcohol on tremors: comparison with propranolol. Neurology. 1984;34:221-222.
37. Rautakorpi I, Martilla RJ, Rinne UK. Alcohol consumption of patients with essential tremor. Acta Neurol Scand. 1983;68:177-179.
38. Bain P, Brin M, Deuschl G, et al. Criteria for the diagnosis of essential tremor. Neurology. 2000;54(suppl 4):S7.
39. Caccia MR, Osio M, Galimberti V, et al. Propranolol, clonidine, urapidil and trazodone infusion in essential tremor: a double-blind crossover trial. Acta Neurol Scand. 1989;79:379-383.
40. Calzetti S, Sasso E, Baratti M, et al. Clinical and computer-based assessment of long-term therapeutic efficacy of propranolol in essential tremor. Acta Neurol Scand. 1990;81:392-396.
41. Calzetti S, Findley LJ, Perucca E, et al. Controlled study of metoprolol and propranolol during prolonged administration in patients with essential tremor. J Neurol Neurosurg Psychiatry. 1982;45:893-897.
42. Cleeves L, Findley LJ. Propranolol and propranolol-LA in essential tremor: a double blind comparative study. J Neurol Neurosurg Psychiatry. 1988;51:379-384.
43. Dupont E, Hansen HJ, Dalby MA. Treatment of benign essential tremor with propranolol. A controlled clinical trial. Acta Neurol Scand. 1973;49:75-84.
44. Jefferson D, Jenner P, Marsden CD. Relationship between plasma propranolol concentration and relief of essential tremor. J Neurol Neurosurg Psychiatry. 1979;42:831-837.
45. Koller WC, Vetere-Overfield B. Acute and chronic effects of propranolol and primidone in essential tremor. Neurology. 1989;39:1587-1588.
46. Teravainen H, Fogelholm R, Larsen A. Effect of propranolol on essential tremor. Neurology. 1976;26:27-30.
47. Tolosa ES, Loewenson RB. Essential tremor: treatment with propranolol. Neurology. 1975;25:1041-1044.
48. Winkler GF, Young RR. The control of essential tremor by propranolol. Trans Am Neurol Assoc. 1971;96:66-68.
49. Baruzzi A, Procaccianti G, Martinelli P, et al. Phenobarbital and propranolol in essential tremor: a double-blind controlled clinical trial. Neurology. 1983;33:296-300.
50. Gorman WP, Cooper R, Pocock P, et al. A comparison of primidone, propranolol, and placebo in essential tremor, using quantitative analysis. J Neurol Neurosurg Psychiatry. 1986;49:64-68.
51. Koller WC. Dose-response relationship of propranolol in the treatment of essential tremor. Arch Neurol. 1986;43:42-43.
52. Koller WC, Royse VL. Efficacy of primidone in essential tremor. Neurology. 1986;36:121-124.
53. McAllister RG Jr, Markesbery WR, Ware RW, et al. Suppression of essential tremor by propranolol: correlation of effect with drug plasma levels and intensity of beta-adrenergic blockade. Ann Neurol. 1977;1:160-166.
54. Wasielewski P, Burns J, Koller W. Pharmacological treatment of tremor. Mov Disord. 1998;13(suppl 3):90-100.
55. Koller. Propranolol therapy for essential tremor of the head. J Neurol. 1984;34:1077-1079.
56. Massey EW, Paulson GW. Essential voice tremor: clinical characteristics and response to therapy. South Med J. 1985;78:316-317.
57. Packer M, Cohn JN, Abraham WT, et al. Consensus recommendations for the management of chronic heart failure. Am J Cardiol. 1999;83:1A-38A.
58. Jefferson D, Jenner P, Marsden CD. Beta-adrenoreceptor antagonists in essential tremor. J Neurol Neurosurg Psychiatry. 1979;42:904-909.
59. Leigh PN, Marsden CD, Twomey A, et al. Beta-adrenoceptor antagonists and essential tremor. Lancet. 1981;16:1106.
60. Larsen TA, Teravainen H, Calne DB. Atenolol vs. propranolol in essential tremor. A controlled, quantitative study. Acta Neurol Scand. 1982;66:547-554.
61. Leigh PN, Jefferson D, Twomey A, et al. Beta-adrenoreceptor mechanisms in essential tremor; a double-blind placebo controlled trial of metoprolol, sotalol and atenolol. J Neurol Neurosurg Psychiatry. 1983;46:710-715.
62. Calzetti S, Findley LJ, Gresty MA, et al. Metoprolol and propranolol in essential tremor: a double-blind, controlled study. J Neurol Neurosurg Psychiatry. 1981;44:814-819.
63. O'Brien MD, Upton AR, Toseland PA. Benign familial tremor treated with primidone. BMJ. 1981;282:178-180.
64. Findley LJ, Cleeves L, Calzetti S. Primidone in essential tremor of the hands and head: a double blind controlled clinical study. J Neurol Neurosurg Psychiatry. 1985;48:911-915.
65. O'Suilleabhain P, Dewey RB. Randomized trial comparing primidone initiation schedules for treating essential tremor. Mov Disord. 2002;17:383-386.
66. Calzetti S, Findley LJ, Pisani F. Phenylethylmalonamide in essential tremor: a double-blind controlled study. J Neurol Neurosurg Psychiatry. 1981;44:932-934.
67. Connor GS. A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology. 2002;59:132-134.
68. Hulihan J, Connor GS, Shu-Chen W, et al. Topiramate in essential tremor: pooled data from a double-blind, placebo-controlled, crossover trial. Neurology. 2003;(suppl):P04. 068.
69. Gunal DI, Afsar N, Bekiroglu N, et al. New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide. Neurol Sci. 2000;21:315-317.
70. Huber SJ, Paulson GW. Efficacy of alprazolam for essential tremor. Neurology. 1988;38:241-243.
71. Ceravolo R, Salvetti S, Piccini P, et al. Acute and chronic effects of clozapine in essential tremor. Mov Disord. 1999;14:468-472.
72. Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand. 1986;73:295-297.
73. Biary N, Koller W. Kinetic predominant essential tremor: successful treatment with clonazepam. Neurology. 1987;37:471-474.
74. Thompson C, Lang A, Parkes JD, et al. A double-blind trial of clonazepam in benign essential tremor. Clin Neuropharmacol. 1984;7:83-88.
75. Caccia MR, Mangoni A. Clonidine in essential tremor: preliminary observations from an open trial. J Neurol. 1985;232:55-57.
76. Koller W, Herbster G, Cone S. Clonidine in the treatment of essential tremor. Mov Disord. 1986;1:235-237.
77. Serrano Duenas M. Acute pharmacological test of clonidine in essential tremor. Neurologia. 1997;12:9-11.
78. Ondo W, Hunter C, Vuong KD, et al. Gabapentin for essential tremor: a multiple-dose, double-blind, placebo-controlled trial. Mov Disord. 2000;15:678-682.
79. Gironell A, Kulisevsky J, Barbanoj M, et al. A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor. Arch Neurol. 1999;56:475-480.
80. Pahwa R, Lyons K, Hubble JP, et al. Double-blind controlled trial of gabapentin in essential tremor. Mov Disord. 1998;13:465-467.
81. Busenbark K, Pahwa R, Hubble J, et al. Double-blind controlled study of methazolamide in the treatment of essential tremor. Neurology. 1993;43:1045-1047. Erratum. Neurology. 1993;43:1910.
82. Busenbark K, Pahwa R, Hubble J, et al. Double-blind controlled study of methazolamide in the treatment of essential tremor. Neurology. 1993;43:1045-1047. Erratum. Neurology. 1993;43:1910.
83. Muenter MD, Daube JR, Caviness JN, et al. Treatment of essential tremor with methazolamide. Mayo Clin Proc. 1991;66:991-997.
84. Biary N, Bahou Y, Sofi MA, et al. The effect of nimodipine on essential tremor. Neurology. 1995;45:1523-1525.
85. Mondrup K, Dupont E, Pedersen E. The effect of the GABA-agonist, progabide, on benign essential tremor. A controlled clinical trial. Acta Neurol Scand. 1983;68:248-252.
86. Koller WC, Rubino F, Gupta S. Pharmacologic probe with progabide of GABA mechanisms in essential tremor. Arch Neurol. 1987;44:905-906.
87. Cleeves L, Findley LJ. Trazodone is ineffective in essential tremor. J Neurol Neurosurg Psychiatry. 1990;53:268-269.
88. Koller WC. Trazodone in essential tremor. Probe of serotoninergic mechanisms. Clin Neuropharmacol. 1989;12:134-137.
89. McLeod NA, White LE Jr. Trazodone in essential tremor. JAMA. 1986;256:2675-2676.
90. Dietrichson P, Espen E. Primidone and propranolol in essential tremor: a study based on quantitative tremor recording and plasma anticonvulsant levels. Acta Neurol Scand. 1987;756:332-340.
91. Koller WC, Biary N, Cone S. Disability in essential tremor: effect of treatment. Neurology. 1986;36:1001-1004. Deleted in proof.
92. Trosch RM, Pullman SL. Botulinum toxin A injections for the treatment of hand tremors. Mov Disord. 1994;9:601-609.
93. Jankovic J, Schwartz K, Clemence W, et al. A randomized, double-blind, placebo-controlled study to evaluate botulinum toxin type A in essential hand tremor. Mov Disord. 1996;11:250-256.
94. Brin MF, Lyons KE, Doucette J, et al. A randomized, double masked, controlled trial of botulinum toxin type A in essential hand tremor. Neurology. 2001;56:1523-1528.
95. Pahwa R, Busenbark K, Swanson-Hyland EF, et al. Botulinum toxin treatment of essential head tremor. Neurology. 1995;45:822-824.
96. Wissl J, Masuhr F, Schelosky L, et al. Quantitative assessment of botulinum toxin treatment in 43 patients with head tremor. Mov Disord. 1997;12:722-726.
97. Hertegard S, Granqvist S, Lindestad PA. Botulinum toxin injections for essential voice tremor. Ann Otol Rhinol Laryngol. 2000;109:204-209.
98. Warrick P, Dromey C, Irish JC, et al. Botulinum toxin for essential tremor of the voice with multiple anatomical sites of tremor: a cross-over design study of unilateral versus bilateral injection. Laryngoscope. 2000;110:1366-1374.
99. Akbostanci MC, Slavin KV, Burchiel KJ. Stereotactic ventral interomedial thalamotomy for the treatment of essential tremor: results of a series of 37 patients. Stereotact Funct Neurosurg. 1999;72:174-177.
100. Tasker RR. Deep brain stimulation is preferable to thalamotomy for tremor suppression. Surg Neurol. 1998;49:145-153. Discussion. Surg Neurol. 1998;49:153-154.
101. Tasker RR. Deep brain stimulation is preferable to thalamotomy for tremor suppression. Surg Neurol. 1998;49:145-153. Discussion. Surg Neurol. 1998;49:153-154.
102. Nagaseki Y, Shibazaki T, Hirai T, et al. Long-term follow-up results of selective VIM-thalamotomy. J Neurosurg. 1986;65:296-302.
103. Goldman MS, Ahlskog JE, Kelly PJ. The symptomatic and functional outcome of stereotactic thalamotomy for medically intractable essential tremor. J Neurosurg. 1992;76:924-928.
104. Jankovic J, Cardoso F, Grossman RG, et al. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery. 1995;37:680-686. Discussion. Neurosurgery. 1995;37:686-687.
105. Jankovic J, Cardoso F, Grossman RG, et al. Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery. 1995;37:680-686. Discussion. Neurosurgery. 1995;37:686-687.
106. Lakie M, Arblaster LA, Roberts RC, et al. Effect of stereotactic thalamic lesion on essential tremor. Lancet. 1992;340:206-207.
107. Selby G. Stereotactic surgery for the relief of Parkinson's disease. 2. An analysis of the results in a series of 303 patients (413 operations). J Neurol Sci. 1967;5:343-375.
108. Matsumoto K, Shichijo F, Fukami T. Long-term follow-up review of cases of Parkinson's disease after unilateral or bilateral thalamotomy. J Neurosurg. 1984;60:1033-1044.
109. Miyamoto T, Bekku H, Moriyama E, et al. Present role of stereotactic thalamotomy for parkinsonism. Retrospective analysis of operative results and thalamic lesions in computed tomograms. Appl Neurophysiol. 1985;48:294-304.
110. Koller W, Pahwa R, Busenbark K, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol. 1997;42:292-299.
111. Ondo W, Jankovic J, Schwartz K, et al. Unilateral thalamic brain stimulation for refractory essential tremor and Parkinson's disease tremor. Neurology. 1998;51:1063-1069.
112. Ondo W, Almaguer M, Jankovic J, et al. Thalamic deep brain stimulation. Arch Neurol. 2001;58:218-222.